- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04907084
Estudio de serina y fenofibrato en pacientes con MacTel tipo 2 (SAFE)
Estudio de fase 2a sobre el efecto de la suplementación con serina y el tratamiento con fenofibrato en los niveles séricos de desoxiesfinganina en pacientes con telangiectasia macular (MacTel) tipo 2 (estudio SAFE)
This is a Phase 2a study of the effect of serine supplementation and fenofibrate treatment on serum deoxysphingolipid levels in patients with macular telangiectasia type 2 (MacTel). This study involves six arms. Participants will be randomly assigned to one of the following treatment groups: serine 200 mg/kg/day, serine 400 mg/kg/day, fenofibrate 160 mg/day, both serine 200 mg/kg/day and fenofibrate 160 mg/day, both serine 400 mg/kg/day and fenofibrate 160 mg/day, or no treatment (control group). Serum deoxysphingolipid levels will be used as the primary outcome, and safety will be evaluated. The participants will be followed for 10 weeks, with visits at Screening, Week 0, 3, 6 and 10.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Additional Procedures include:
- Fasting blood work
- Collection of microbiome samples
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory University
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48105
- Kellogg Eye Center, University of Michigan
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44122
- Retina Associates of Cleveland
-
-
Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37922
- Southeastern Retina Associates
-
-
Texas
-
Bellaire, Texas, Estados Unidos, 77401
- Retina Consultants of Texas
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84132
- Moran Eye Center, University of Utah
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98104
- University of Washington
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- The Eye Institute, Medical College of Wisconsin
-
-
-
-
-
London, Reino Unido, ECV2PD
- Moorfields Eye Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Signed and dated written informed consent obtained from the participant in accordance with the local regulations;
- Males/females 21 years of age or older;
- English speaking;
- Enrolled in the Natural History Observation and Registry Study (NHOR) and diagnosed with confirmed MacTel type 2 in at least one eye;
- Willing to use contraception, if applicable; and
- Willing to comply with study protocol and follow-up visits.
Exclusion Criteria:
- Participant is unable to provide informed consent;
- Participant is less than 21 years of age;
- Participant is currently taking, or has taken within four weeks prior to screening, a serine or glycine supplement;
- Participant is currently taking, or has taken within 12 months prior to screening, fibrates including clofibrate, ciprofibrate, bezafibrate, fenofibrate, and gemfibrozil;
- Participant is currently taking an anticoagulant, colchicine, cyclosporine, tacrolimus or bile acid binding resins;
- Participant has known allergy to fibrates and/or serine;
- Participant has a known history of clinically significant myopathy or myalgia related to cholesterol-lowering drugs;
- Participant has active liver disease and/or elevated liver enzymes*;
- Participant has renal dysfunction as evidenced by elevated serum creatinine* and/ or glomerular filtration rate (GFR) less than 90 mL/min;
- Participant has thrombocytopenia as evidenced by a platelet count below 100,000 per microliter, anemia as evidenced by hemoglobin levels below 10 g/dL, or history of bleeding disorder;
- Participant has a history of gallbladder disease or has had a cholecystectomy;
- Participant has triglyceride levels greater than 400 mg/dL on treatment, or greater than 700 mg/dL on no treatment;
- Participant has untreated/uncured Hepatitis C, or a history of Hepatitis B, autoimmune hepatitis, or HIV;
- Participant has had any malignancies within the last 5 years (not including basal cell carcinoma);
- Participant has ever been enrolled in a clinical trial involving ciliary neurotrophic factor (CNTF) treatment;
- Participant is currently enrolled in another clinical trial that involves treatment or participated in one within the last 30 days;
- Participant is pregnant, breastfeeding or planning a pregnancy;
- Participant is medically unable to comply with study procedures or follow-up visits;
- Participant has, in the opinion of the Investigator, any physical or mental condition that would increase the patient's risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments; or
- Patient is unavailable for follow-up visits. *based on reference range for the local laboratory used
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación factorial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Serine 200 mg/kg/day
Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)). |
Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally) |
|
Experimental: Serine 400 mg/kg/day
Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)). |
Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally) |
|
Experimental: Fenofibrate 160 mg/day
Fenofibrate 160 mg per day. To be taken once per day for 6 weeks. |
Fenofibrate 160mg pill, taken orally |
|
Experimental: Serine 200 mg/kg/day and Fenofibrate 160 mg/day
Serine 200 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)). Fenofibrate 160 mg per day. To be taken once per day for 6 weeks. |
Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally) Fenofibrate 160mg pill, taken orally |
|
Experimental: Serine 400 mg/kg/day and Fenofibrate 160 mg/day
Serine 400 mg/kg per day. To be taken once per day for 6 weeks. Exact dose dependent on participant's weight (in kg)). Fenofibrate 160 mg per day. To be taken once per day for 6 weeks. |
Powdered serine supplement (Dosed out individually per participant. Participant to mix with water and ingest orally) Fenofibrate 160mg pill, taken orally |
|
Sin intervención: No treatment
Control group: no investigational product taken |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety Assessment
Periodo de tiempo: Reported over the10 weeks from baseline to exit visit
|
Safety assessment measured via examined AEs and SAEs (during study visits) and via participant self-reported AEs and SAEs that occurred between visits |
Reported over the10 weeks from baseline to exit visit
|
|
Percentage Change of Serum Deoxysphingolipid Levels From Baseline to 6 Weeks
Periodo de tiempo: Blood draw at baseline and 6 weeks on product
|
Percentage change in the sum of 7 different deoxy-dihydroceramides species detected. Negative values mean these metabolites decreased during the treatment period. Deoxy-sphingolipids were measured in serum using LC-MS. |
Blood draw at baseline and 6 weeks on product
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage Change in Serum Lipid Levels From Baseline to 6 Weeks
Periodo de tiempo: blood draws from baseline and week 6 on product
|
Percent changes in lipid levels measured between baseline and 6 weeks. These lipid levels were obtained from the local clinical lab at each site as part of a lipid panel. Negative values mean these metabolites decreased during the treatment period. |
blood draws from baseline and week 6 on product
|
|
Percentage Change in Serum Serine and Glycine Levels From Baseline to 6 Weeks
Periodo de tiempo: blood draws from baseline and week 6 on product
|
Percentage change in fasting levels of the two amino acids serine and glycine. Serine supplementation is part of the treatment and glycine can be produced from serine by different cells in the body. Serine and glycine levels were measured from serum using LC-MS. |
blood draws from baseline and week 6 on product
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Mari A Gantner, PhD, Lowy Medical Research Institute
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Aminoácidos, péptidos y proteínas
- Químicos orgánicos
- Éter
- Hidrocarburos
- Hidrocarburos, cíclico
- Ácidos, acíclico
- Ácidos carboxílicos
- Hidrocarburos, aromáticos
- Aminoácidos
- Fenoles
- Derivados de benceno
- Butiratos
- Fenilo éter
- Cetonas
- Ácidos fibrios
- Isobutiratos
- Benzofenones
- Aminoácidos, neutral
- Fenofibrato
- Serina
Otros números de identificación del estudio
- 2020-002
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .